ADAAdenosine deaminase
ADEMAcute disseminated encephalomyelitis
AHSCTAutologous haematopoietic stem cell transplantation
AMLAcute myelogenous leukaemia; acute myeloid leukaemia
AOSDAdult-onset Still’s disease
ASCTAllogeneic stem cell transplantation
BMTBone marrow transplantation
CISClinically isolated syndrome
CNSCentral nervous system
CSFCerebrospinal fluid
CTLCytotoxic T lymphocytes
DCKDeoxycytidine kinase
DHODHDihydroorotate dehydrogenase 
DMFDimethyl fumarate
DMTDisease-modifying therapy
DRESSDrug reaction with eosinophilia and systemic symptoms
EBVEpstein-Barr virus
EDSSExpanded Disability Status Scale
EIDExtended interval dosing
EMAEuropean Medicines Agency
EPEvoked potential
FBCFull blood count
FDAFederal Drug Administration
GCNGranule cell neuronopathy
GnRHGonadotropin-releasing hormone
HCPHealthcare professional
HIVHuman immunodeficiency virus
HLAHuman leukocyte antigen
HLHHaemophagocytic lymphohistiocytosis
HPVHuman papillomavirus
HSCTHaematopoietic stem cell transplantation
IRISImmune reconstitution inflammatory syndrome
IRTImmune reconstitution therapy
ITPImmune thrombocytopenic purpura
IVFIn vitro fertilisation
iviIntravenous infusion
JCVJC virus
LFTLiver function test
LVEFLeft ventricular ejection fraction
MCSMicroscopy, culture and sensitivity (urine test)
MEDAMinimal evidence of disease activity
METMaintenance/escalation therapy
MMFMonomethyl fumarate
MRIMagnetic resonance imaging
MUGAMultigated acquisition (scan)
NAbsNeutralising antibodies
NEDANo evident disease activity
NEIDANo evident inflammatory disease activity
NFLNeurofilament light
NHSNational Health Service
NIRTNon-selective immune reconstitution therapy
NKNatural killer
NMONeuromyelitis optica
OCBOligoclonal bands
OCTOptic coherence tomography
PALSPatient Advice and Liaison Service
PCPPneumocystis pneumonia
PCRPolymerase chain reaction
PIRAProgression independent of relapses
PMLProgressive multifocal leukoencephalopathy
PPMSPrimary progressive MS
PRESposterior reversible encephalopathy syndrome
PRMSProgressive relapsing MS
PROMSPatient-related outcome measures
RESRapidly evolving severe MS
RISRadiologically isolated syndrome
RRMSRelapsing–remitting MS
RSPMSRelapsing secondary progressive MS
S1PSphingosine 1-phosphate
SAPSingle-attack progressive MS
SIRStandardised incidence rate
SIRTSelective immune reconstitution therapy
SLESystemic lupus erythematosus
SmPCSummary of product characteristics
SPMSSecondary progressive MS
TB ELISpotTuberculosis enzyme-linked immune absorbent spot
TBITotal body irradiation
TFTThyroid function test
TLITotal lymphoid irradiation
TTPThrombotic thrombocytopenic purpura
U&EUrea and electrolytes
VZVVaricella zoster virus